Long-term safety of adalimumab in clinical trials in adult patients with Crohn’s disease or ulcerative colitis.

Long-term safety of adalimumab in clinical trials in adult patients with Crohn’s disease or ulcerative colitis. Aliment Pharmacol Ther. 2017 Nov 21;: Authors: Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H Abstract BACKGROUND: Adalimumab is used to treat moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC) when conventional therapies fail. AIM: To update long-term adalimumab safety from CD and UC trials; the previous report was…

Read More

Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn’s disease.

Related Articles Clinical and pharmacokinetic factors associated with adalimumab-induced mucosal healing in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017 Nov 02;: Authors: Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group Abstract BACKGROUND & AIMS: We previously reported results from a prospective randomized controlled trial comparing the efficacy of adalimumab monotherapy vs combination with azathioprine for patients with Crohn’s…

Read More

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study. World J Gastroenterol. 2017 Oct 21;23(39):7139-7149 Authors: Luchetti MM, Benfaremo D, Ciccia F, Bolognini L, Ciferri M, Farinelli A, Rossini M, Mosca P, Triolo G, Gabrielli A Abstract AIM: To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS: A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular…

Read More

Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease.

Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease. J Gastroenterol Hepatol. 2017 Oct 31;: Authors: Tanaka H, Kamata N, Yamada A, Endo K, Fujii T, Yoshino T, Sugaya T, Yokoyama Y, Bamba S, Umeno J, Yanai Y, Ishii M, Kawaguchi T, Shinzaki S, Toya Y, Kobayashi T, Nojima M, Hibi T, ADJUST study group Abstract BACKGROUND AND AIM: There are few studies on the long-term efficacy of adalimumab treatment for patients with Crohn’s disease. We have conducted a large, multicenter, retrospective cohort study…

Read More

Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.

Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis. 2017 Jul 17;: Authors: Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J Abstract Background and Aims: Randomised trials have described the benefits of adalimumab [ADA] for ulcerative colitis [UC]; however, few data are available on health-related quality of life [HRQL] and…

Read More

Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn’s disease: a subanalysis of the DIAMOND trial.

Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn’s disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017 Sep 08;: Authors: Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group Abstract BACKGROUND: Significance of monitoring adalimumab trough levels and anti-adalimumab antibodies (AAA) for disease outcome in Crohn’s disease (CD)…

Read More

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn’s disease.

Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn’s disease. J Gastroenterol Hepatol. 2017 Aug 30;: Authors: Sugita N, Watanabe K, Kamata N, Yukawa T, Otani K, Hosomi S, Nagami Y, Tanaka F, Taira K, Yamagami H, Tanigawa T, Shiba M, Watanabe T, Tominaga K, Kabata D, Shintani A, Arakawa T, Fujiwara Y Abstract BACKGROUND AND AIM: Secondary loss of response to adalimumab (ADA-LOR) commonly occurs in patients with Crohn’s disease (CD) treated with ADA. We evaluated the efficacy of…

Read More

Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea.

Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea. Dig Dis Sci. 2017 Aug 18;: Authors: Seo H, Ye BD, Song EM, Lee SH, Chang K, Lee HS, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK Abstract BACKGROUND AND AIMS: Large-scale studies regarding the long-term outcomes of adalimumab (ADA) treatment in Asian patients with Crohn’s disease (CD) are still scarce. METHODS: We retrospectively analyzed the long-term outcomes of ADA treatment in Korean CD patients who commenced…

Read More

Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn’s Disease.

Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn’s Disease. Inflamm Bowel Dis. 2017 Aug 03;: Authors: Kariyawasam VC, Ward MG, Blaker PA, Patel KV, Goel R, Sanderson JD, Irving PM Abstract BACKGROUND: The benefit of concomitant immunomodulation with adalimumab (ADA) in Crohn’s disease is poorly understood. We aimed to compare ADA monotherapy with combination therapy with thiopurines, stratified by thioguanine nucleotides (TGNs). METHODS: Retrospective observational study of…

Read More
<< Go Back